重性抑郁障碍与双相障碍及大麻使用障碍的共病与共聚集:一项对照家系研究
该横断面社区研究纳入586名先证者(186例双相障碍,55例CUD)和698名一级亲属,采用半结构化访谈评估终生DSM-IV障碍。先证者CUD与亲属CUD风险升高相关(aOR 2.64),先证者BP-II亦与亲属CUD风险升高相关(aOR 2.57);亲属中BP-II和MDD均与CUD相关。心境障碍多数先于CUD起病,提示BP-II干预可能有助于CUD预防。
要点
- 先证者CUD与亲属CUD风险升高相关(aOR 2.64,95%CI 1.20-5.79)。
- 先证者BP-II与亲属CUD风险升高相关(aOR 2.57,95%CI 1.06-6.23)。
- 亲属中BP-II和MDD均与CUD相关,心境障碍多数先于CUD起病。
核心结论
- 研究证实CUD存在家族聚集性,BP-II先证者亲属CUD风险升高提示CUD可能与BP-II共享共同素质。
- 结合抑郁和躁狂先于CUD起病,这些发现突出BP-II干预作为CUD预防的潜在作用。
研究设计与样本
- 横断面、社区为基础的研究,于2004年5月至2020年8月在华盛顿特区大都市区招募。
- 共纳入586名成年先证者(186例双相障碍;55例CUD)和698名一级亲属(91例双相障碍;68例CUD)。
- 采用半结构化诊断访谈和家族史报告评估终生DSM-IV障碍,使用混合效应模型估计家族聚集和共聚集,调整年龄、性别、招募来源及共病心境、焦虑和其他物质使用障碍。
主要发现
- 先证者CUD(55例,9.4%)与亲属CUD风险升高相关(aOR 2.64;95%CI 1.20-5.79;P=.02)。
- 先证者BP-II(72例,12.3%)与亲属CUD风险升高相关(aOR 2.57;95%CI 1.06-6.23;P=.04)。
- 先证者BP-I(114例,19.5%)和MDD(192例,32.8%)与亲属CUD无显著关联。
- 亲属中CUD与BP-II相关(aOR 4.50;95%CI 1.72-11.77;P=.002),与MDD相关(aOR 3.64;95%CI 1.78-7.45;P<.001)。
- 亲属中CUD者平均年龄42.7(12.8)岁 vs 无CUD者50.3(18.3)岁(aOR 0.98;95%CI 0.96-1.00;P=.02)。
关键数值与推荐
- BP-II与CUD的家族共聚集在纳入共病焦虑障碍后减弱。
- 亲属CUD率在有家族性和个体性BP-II史者最高:无家族性或个体性BP-II史41例(7.2%);有家族性但无个体性BP-II史13例(19.1%);有个体性但无家族性BP-II史10例(22.2%);有家族性和个体性BP-II史4例(28.6%);Fisher精确检验P<.001。
- 心境障碍亚型在先证者和亲属中多数先于CUD起病。
临床怎么用
- BP-II先证者的一级亲属CUD风险升高,提示对该人群可关注CUD风险。
- 心境障碍多数先于CUD起病,结合家族聚集性发现,BP-II干预可能对CUD预防有潜在作用。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Cannabis use disorder (CUD) is increasing in the US. Clarification of the potential mechanisms underlying the comorbidity between mood disorders and CUD may help prevent CUD. OBJECTIVE: To examine co-occurrence and familial aggregation of CUD and mood disorder subtypes. DESIGN, SETTING, AND PARTICIPANTS: In this cross-sectional, community-based study in the Washington, DC, metropolitan area, semistructured diagnostic interviews and family history reports assessed lifetime DSM-IV disorders in probands and relatives. Familial aggregation and coaggregation of CUD with mood disorders were estimated via mixed-effects models, adjusting for age, sex, recruitment source, and comorbid mood, anxiety, and other substance use disorders. A total of 586 adult probands (186 with bipolar disorder; 55 with CUD) and 698 first-degree relatives (91 with bipolar disorder; 68 with CUD) were recruited from a community screening of the greater Washington, DC, metropolitan area from May 2004 to August 2020. Inclusion criteria were ability to speak English, and availability and consent to contact at least 2 living first-degree relatives. MAIN OUTCOMES AND MEASURES: Lifetime CUD in first-degree relatives. RESULTS: Of 586 probands, 395 (67.4%) were female; among 698 relatives, 437 (62.6%) were female. The mean (SD) age was 47.5 (15.2) years for probands and 49.6 (18.0) years for relatives. In the proband group, 82 participants (14.0%) self-identified as African American or Black, 467 (79.7%) as White, and 37 (6.3%) as American Indian or Alaska Native, Asian, more than one race, or another race or ethnicity or declined to respond. In the relative group, 53 participants (7.6%) self-identified as African American or Black, 594 (85.1%) as White, and 51 (7.3%) as American Indian or Alaska Native, Asian, more than one race, or another race or ethnicity or declined to respond. These groups were combined to protect privacy owing to small numbers. CUD in probands (55 [9.4%]) was associated with an increase in CUD in relatives (adjusted odds ratio [aOR], 2.64; 95% CI, 1.20-5.79; P = .02). Bipolar disorder II (BP-II) in probands (72 [12.3%]) was also associated with increased risk of CUD in relatives (aOR, 2.57; 95% CI, 1.06-6.23; P = .04). However, bipolar disorder I (114 [19.5%]) and major depressive disorder (192 [32.8%]) in probands were not significantly associated with CUD in relatives. Among relatives, CUD was associated with BP-II (aOR, 4.50; 95% CI, 1.72-11.77; P = .002), major depressive disorder (aOR, 3.64; 95% CI, 1.78-7.45; P < .001), and mean (SD) age (42.7 [12.8] years with CUD vs 50.3 [18.3] years without CUD; aOR, 0.98; 95% CI, 0.96-1.00; P = .02). Familial coaggregation of BP-II with CUD was attenuated by the inclusion of comorbid anxiety disorders. Further, rates of CUD were highest in relatives with both a familial and individual history of BP-II (no familial or individual history of BP-II: 41 [7.2%]; familial history but no individual history of BP-II: 13 [19.1%]; individual history but no familial history of BP-II: 10 [22.2%]; familial and individual history of BP-II: 4 [28.6%]; Fisher exact test, P < .001). The onset of mood disorder subtypes preceded CUD in probands and relatives in most cases. CONCLUSIONS AND RELEVANCE: The findings confirmed a familial aggregation of CUD. The increase in risk of CUD among relatives of probands with BP-II suggests that CUD may share a common underlying diathesis with BP-II. Taken together with the temporal precedence of depression and mania with respect to CUD onset, these findings highlight a potential role for BP-II intervention as CUD prevention.
引用
- Quick CR, Conway KP, Swendsen J, et al. Comorbidity and Coaggregation of Major Depressive Disorder and Bipolar Disorder and Cannabis Use Disorder in a Controlled Family Study. JAMA Psychiatry. 2022. PMID: 35648395. doi:10.1001/jamapsychiatry.2022.1338
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。